| Trial ID # | NCT04781088 |
| Phase | II |
| Drug Class | Angiogenesis Inhibitors: Multi-targeted RTK |
| Drug Name | Lenvatinib |
| Alternate Drug Names | MK-7902, Lenvima, ER-203492-00, E7080 |
| Drugs in Trial | Lenvatinib, Paclitaxel, Pembrolizumab |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 24 ovarian, median 2 prior therapies (1-3) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DoR, PFS, evaluated per RECIST |
| Efficacy | ORR: 47% (2CR, 9PR, n=24) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | Encouraging activity is seen in ovarian cancer; the regimen is tolerable with manageable side effects; however, a high number of patients discontinued treatment for toxicity per protocol or patient preference |
| Reference | Backer FJ et al. A phase II study of weekly paclitaxel, lenvatinib and pembrolizumab among patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer. SGO (2024) |